Affiliated Medical Services Laboratory, INC.

Affiliated Medical Services Laboratory, INC. was paid $5.89M by Medicaid between Jan 2018 and Sep 2022, across 192 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kansas

Rank by total paid#6 of 47

Median peer was paid$64K

This provider vs. median92×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	197,964	$1.11M
2019	154,494	$1.03M
2020	130,965	$1.09M
2021	141,087	$1.45M
2022	113,423	$1.20M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	15%	17,044	15,306	$867K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	6.4%	11,245	10,369	$379K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.4%	11,220	10,346	$378K
80053	Comprehensive metabolic panel	5.3%	52,092	44,543	$313K
84443	Thyroid stimulating hormone (TSH)	4.3%	29,398	26,677	$256K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	4.3%	3,524	3,210	$254K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.4%	11,179	10,490	$201K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.8%	69,373	56,615	$164K
83036	Hemoglobin; glycosylated (A1C)	2.7%	25,621	22,698	$160K
80061	Lipid panel	2.7%	21,622	19,531	$157K
87086	Culture, bacterial; quantitative colony count, urine	2.6%	25,476	22,233	$153K
87800		2.3%	7,850	7,255	$136K

180 more codes

87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	2.3%	5,962	$134K
86003		2.2%	2,604	$127K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	2.0%	5,924	$117K
87653		1.7%	2,644	$100K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.5%	3,102	$87K
87186		1.2%	11,650	$73K
85027		1.1%	14,703	$65K
83655		1.1%	5,692	$64K
80048	Basic metabolic panel (calcium, ionized)	1.1%	22,928	$64K
86780		1.1%	4,720	$63K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.1%	7,024	$62K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	2,269	$59K
83516		<1%	2,753	$58K
84439		<1%	7,385	$50K
87077		<1%	10,367	$48K
82607		<1%	5,311	$44K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	8,311	$44K
83013		<1%	917	$42K
82728		<1%	3,829	$39K
80074		<1%	1,685	$38K
82784		<1%	3,021	$37K
84146		<1%	1,741	$33K
86140		<1%	8,326	$32K
87070		<1%	6,310	$32K
87340		<1%	3,695	$32K
87081		<1%	4,774	$30K
86850		<1%	4,869	$30K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	146	$29K
81001		<1%	17,789	$28K
82746		<1%	3,731	$28K
85652		<1%	8,995	$27K
86803		<1%	2,006	$27K
86480		<1%	642	$27K
80069		<1%	5,766	$24K
84403		<1%	1,236	$24K
86255		<1%	1,663	$23K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	642	$22K
83880		<1%	3,104	$20K
80164		<1%	3,066	$20K
84702		<1%	2,602	$20K
83970		<1%	2,355	$19K
83735		<1%	6,308	$19K
83690		<1%	2,991	$19K
86038		<1%	1,582	$18K
81025		<1%	3,025	$18K
84153		<1%	1,688	$18K
87147		<1%	3,210	$17K
86762		<1%	2,948	$17K
85610		<1%	11,854	$16K
84481		<1%	1,032	$16K
82950		<1%	2,537	$15K
83001		<1%	745	$14K
82570		<1%	4,723	$14K
82150		<1%	2,255	$14K
80081		<1%	204	$13K
86901		<1%	3,121	$13K
83540		<1%	4,900	$12K
80076		<1%	2,110	$11K
83550		<1%	1,680	$11K
88142		<1%	782	$10K
82785		<1%	1,175	$10K
83002		<1%	542	$10K
86900		<1%	3,157	$10K
88141		<1%	604	$8K
82977		<1%	1,404	$8K
84466		<1%	872	$8K
84550		<1%	3,339	$8K
87075		<1%	1,025	$7K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	628	$7K
82043		<1%	2,862	$6K
82550		<1%	1,518	$6K
84156		<1%	2,899	$6K
86376		<1%	383	$6K
81003		<1%	7,330	$6K
86431		<1%	1,084	$6K
82247		<1%	1,640	$6K
87210		<1%	1,542	$6K
84100		<1%	2,087	$6K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	483	$5K
80177		<1%	734	$5K
83615		<1%	1,094	$5K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	988	$5K
82248		<1%	2,385	$5K
82947		<1%	1,716	$4K
82140		<1%	988	$4K
80178		<1%	798	$3K
84460		<1%	1,195	$3K
82670		<1%	114	$3K
83020		<1%	199	$3K
86592		<1%	1,154	$3K
87503		<1%	408	$3K
81015		<1%	2,761	$3K
85018		<1%	2,342	$3K
84145		<1%	703	$2K
83525		<1%	257	$2K
87522	Neg quan hep c or qual rna	<1%	403	$2K
85014		<1%	1,918	$2K
86677		<1%	432	$2K
80197		<1%	444	$2K
86787		<1%	254	$2K
82951		<1%	98	$2K
86258		<1%	151	$2K
80047		<1%	111	$2K
86696		<1%	89	$2K
86800		<1%	103	$2K
82565		<1%	908	$1K
86231		<1%	272	$1K
86256		<1%	102	$1K
83021		<1%	89	$1K
86706		<1%	174	$1K
84484		<1%	269	$1K
84450		<1%	623	$1K
85379		<1%	363	$1K
85730		<1%	327	$1K
86200		<1%	115	$1K
87205		<1%	391	$1K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	26	$1K
80185		<1%	349	$993.98
87045		<1%	126	$909.72
84402		<1%	71	$876.80
87427		<1%	101	$869.06
84134		<1%	439	$817.72
84703		<1%	105	$798.03
85045		<1%	251	$790.45
87209		<1%	44	$702.62
82310		<1%	555	$602.01
82533		<1%	57	$590.98
86665		<1%	43	$576.90
82105		<1%	105	$557.31
86704		<1%	69	$525.65
86695		<1%	89	$502.03
82274		<1%	483	$474.17
86317		<1%	88	$464.49
85007		<1%	539	$444.70
84155		<1%	480	$443.27
80156		<1%	72	$422.32
87046		<1%	126	$412.30
82040		<1%	427	$408.69
84436		<1%	96	$391.41
84075		<1%	349	$368.42
86308		<1%	65	$353.05
87529		<1%	46	$348.80
36415	Collection of venous blood by venipuncture	<1%	40,022	$323.11
86664		<1%	42	$283.62
87807		<1%	23	$283.51
86663		<1%	42	$282.71
87177		<1%	44	$276.84
83721		<1%	72	$275.05
82952		<1%	56	$259.79
87449		<1%	13	$237.64
80050	General health panel	<1%	243	$234.46
87338		<1%	15	$229.35
87040		<1%	32	$215.14
80183		<1%	14	$198.23
84305		<1%	13	$195.72
84480		<1%	27	$195.25
86161		<1%	13	$184.57
87493		<1%	27	$177.12
80162		<1%	72	$94.13
83010		<1%	13	$82.17
84165		<1%	15	$77.23
80051		<1%	433	$75.03
80363		<1%	14	$70.80
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	20,904	$68.79
84132		<1%	103	$55.53
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	271	$47.00
84520		<1%	406	$37.80
83605		<1%	16	$31.44
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	19,994	$24.64
83883		<1%	250	$18.80
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	29,447	$11.81
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	52	$6.35
83520		<1%	84	$4.65
36416		<1%	116	$2.34
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	86	$1.04
G0475	Hiv antigen/antibody, combination assay, screening	0%	26	$0.00
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	0%	12	$0.00
0115U		0%	18	$0.00
86789		0%	16	$0.00
0225U		0%	42	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHARNED, EDWIN (PRESIDENT AND CEO)